Development and characterization of nanostructure lipid carrier for anti-hepatitis-C virus drug
EL-Badry, M., Mahmoud, O., Fathalla, D., EL-Gendy, G. (2024). Development and characterization of nanostructure lipid carrier for anti-hepatitis-C virus drug. EKB Journal Management System, 7(1), 18-25. doi: 10.21608/jabps.2023.234602.1202
Mahmoud EL-Badry; Ominia Ali Mahmoud; Dina Fathalla; Gamal EL-Gendy. "Development and characterization of nanostructure lipid carrier for anti-hepatitis-C virus drug". EKB Journal Management System, 7, 1, 2024, 18-25. doi: 10.21608/jabps.2023.234602.1202
EL-Badry, M., Mahmoud, O., Fathalla, D., EL-Gendy, G. (2024). 'Development and characterization of nanostructure lipid carrier for anti-hepatitis-C virus drug', EKB Journal Management System, 7(1), pp. 18-25. doi: 10.21608/jabps.2023.234602.1202
EL-Badry, M., Mahmoud, O., Fathalla, D., EL-Gendy, G. Development and characterization of nanostructure lipid carrier for anti-hepatitis-C virus drug. EKB Journal Management System, 2024; 7(1): 18-25. doi: 10.21608/jabps.2023.234602.1202

Development and characterization of nanostructure lipid carrier for anti-hepatitis-C virus drug

Journal of Advanced Biomedical and Pharmaceutical Sciences
Article 2, Volume 7, Issue 1, January 2024, Page 18-25  XML PDF (637.74 K)
Document Type: Original Article
DOI: 10.21608/jabps.2023.234602.1202
View on SCiNiTO View on SCiNiTO
Authors
Mahmoud EL-Badry email orcid 1; Ominia Ali Mahmoud2; Dina Fathalla3; Gamal EL-Gendy4
1Dept of Pharmaceutics Faculty of Pharmacy Assiut University
2Department of pharmaceutics, Faculty of pharmacy, Sohag University
3Faculty of Pharmacy, Assiut university
4Department of Pharmaceutics, Faculty of pharmacy, Assiut University
Abstract
Abstract

Velpatasvir (VLP) as, a medication used to treat hepatitis-C virus (HCV). It has a very low oral bioavailability (25%). The aim of the current work is to prepare VLP loaded nanostructured lipid carriers (VLP-NLCs) as a potential way to enhance VLP aqueous solubility and bioavailability and increase its efficacy. The preparation of VLP-NLCs was carried out using the emulsification - solvent evaporation method, followed by ultrasonication. The prepared nanocarrier was examined for its particle size, zeta potential, entrapment efficiency and in-vitro drug release of the selected formula. VLP-NLCs displayed narrow size distribution, spherical morphologies that were nanosized (105 ± 2.3 nm), and significant drug entrapment efficiencies (> 80%). Particle size ranged between 105 ± 2.3 to 1399 ± 2.8 nm and zeta potential between -14.6 ± 0.2 to -46.0 ± 1.1 mV. High entrapping efficiency was obtained due to incorporation of liquid lipid. The In Vitro release showed prolonged time dependent release. NLC 6 had the best results among the eight prepared formulae. These findings show that NLC is a potential carrier to improve the solubility of drug and enhance its bioavailability.
Keywords
Velpatasvir; HCV; Nanostructured lipid carriers (NLCs); particle size; in-vitro drug release
Statistics
Article View: 344
PDF Download: 478